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Aims Humans with inactivating mutations in peroxisomal proliferators activated receptor gamma (PPARg) typically develop
a complex metabolic syndrome characterized by insulin resistance, diabetes, lipodystrophy, hypertension, and dysli-
pidaemia which is likely to increase their cardiovascular risk. Despite evidence that the activation of PPARg may
prevent cardiac fibrosis and hypertrophy, recent evidence has suggested that pharmacological activation of PPARg
causes increased cardiovascular mortality. In this study, we investigated the effects of defective PPARg function on
the development of cardiac fibrosis and hypertrophy in a murine model carrying a human dominant-negative
mutation in PPARg.
Methods
and results
Mice with a dominant-negative point mutation in PPARg (P465L) and their wild-type (WT) littermates were treated
with either subcutaneous angiotensin II (AngII) infusion or saline for 2 weeks. Heterozygous P465L and WT mice
developed a similar increase in systolic blood pressure, but the mutant mice developed significantly more severe
cardiac fibrosis to AngII that correlated with increased expression of profibrotic genes. Both groups similarly
increased the heart weight to body weight ratio compared with saline-treated controls. There were no differences
in fibrosis between saline-treated WT and P465L mice.
Conclusion These results show synergistic pathogenic effects between the presence of defective PPARg and AngII-induced
hypertension and suggest that patients with PPARg mutation and hypertension may need more aggressive therapeutic
measures to reduce the risk of accelerated cardiac fibrosis.
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Introduction
Peroxisomal proliferators activated receptor gamma (PPARg) is an
important transcription factor that controls metabolic aspects such
as adipogenesis and insulin sensitivity. Its relevance in controlling
energy homeostasis is illustrated by the fact that humans with
mutations in PPARg typically develop severe metabolic compli-
cations characterized by insulin resistance, diabetes, lipodystrophy,
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hypertension, and dyslipidaemia; a cluster of metabolic alterations
known to increase cardiovascular risk.1 There is evidence that the
activation of PPARg using thiazolidinediones improves the meta-
bolic control of diabetic patients2 and that agonism of the
PPARg receptor may provide added beneficial cardiovascular
effects by preventing cardiac fibrosis and hypertrophy.3
However, the potential cardiovascular beneficial effects of
PPARg agonism have recently been questioned based on the evi-
dence that rosiglitazone treatment to diabetic individuals may
cause an increase in cardiovascular mortality of an unclear mech-
anism.4,5 This observation has important clinical implications not
only for its impact of treatment with PPARg agonists on the thera-
peutic management and mental health of the diabetic population,
but also for a relatively small subset of patients with mutations in
PPARg affected by a severe metabolic phenotype. In this study,
we use a genetically humanized mouse model harbouring a well-
characterized human PPARg dominant-negative mutation to
determine the effects of defective PPARg function on cardiac
contraction, fibrotic and hypertrophic responses under basal
conditions and in the context of angiotensin II (AngII)-induced
hypertension.
Hypertensive heart disease and cardiac hypertrophy, often
associated with insulin resistance, are leading causes of high mor-
bidity and mortality due to the predisposition to the development
of congestive cardiac failure and sudden death. During this process,
remodelling of the heart takes place contributing to persistent con-
tractile dysfunction6 and in numerous cases to arrhythmia.7
Although the precise mechanisms underlying cardiac remodelling
remain under intensive investigation, the involvement of increased
activity of the renin–angiotensin–aldosterone system is well
recognised7—as indicated by experimental models of aldosterone
or AngII-induced hypertension where a similar process of remo-
delling occurs.8
Despite its low abundance in the heart, a direct role of PPARg in
cardiac hypertrophy has been hypothesised previously. It has been
suggested that maximal transcriptional activity of PPARg may delay
the development of this pathological condition as indicated by the
fact that ligands of PPARg (troglitazone, pioglitazone, 15d-PGJ2)
are able to prevent AngII-induced hypertrophy of neonatal rat car-
diomyocytes.9,10 Conversely, pioglitazone only marginally attenu-
ated the hypertrophic response during pressure overload in mice
that were heterozygous for deficient PPARg compared with
their wild-type (WT) littermates.10
The role of PPARg in cardiac fibrosis is not fully understood.
Remodelling and fibrosis take place following myocardial ischaemia,
with an increase in myocardial collagen deposition, and predis-
poses to the development of heart failure. There is data suggesting
that pioglitazone in mice11 and rosiglitazone in rats12 may reduce
post-ischaemic myocardial collagen content and the degree of
fibrosis, when these PPARg ligands were administered after ischae-
mia. Similarly, in cardiac hypertrophy induced by transverse aortic
constriction in rats, the PPARg ligand rosiglitazone reduced col-
lagen deposition and cardiac fibrosis.13
In this study, we use a genetic approach to investigate the effects
of a human equivalent mutation of PPARg (P465L dominant-
negative point mutation) on the hypertrophic and fibrotic
responses to chronic AngII-induced hypertension.
Methods
Animals
Peroxisomal proliferators activated receptor gamma (P465L) mice
were generated as described before.14 The age of 14-week-old male
WT and heterozygous (P465L) littermate mice carrying ‘knock-in’
mutation were used in this study. Homozygous allelic combination of
this mutation causes embryonic lethality. Experiments were performed
in accordance with the Guidance on the Operation of Animals (Scien-
tific Procedure) Acts, 1986 (UK).
Experimental protocol
Osmotic minipumps (Alzet Model 1002, Charles River UK Ltd,
Margate, UK) releasing either AngII at a dose of 1.1 mg kg21 day21
for 14 days or saline were implanted subcutaneously under isoflurane
anaesthesia (2% isoflurane+98% O2). Wild-type and P465L heterozy-
gous animals were randomized into the following experimental
groups: WT mice treated with saline (WT/Sal; total n = 11), P465L het-
erozygous mice treated with saline (P465L/Sal; total n = 11), WT mice
treated with AngII (WT/AngII; total n = 21), and P465L heterozygous
mice treated with AngII (P465L/AngII; total n = 22).
Non-invasive blood pressure measurement
Systolic blood pressure was measured by tail cuff plethysmography
(Kent Scientific, Kings Hill, UK) in conscious mice at a temperature
of 268C following a 3 days training session. Blood pressure was
measured on day 0, 7, and 14.
Cardiac functional assessment by
echocardiography
Under isoflurane anaesthesia (1.5% isoflurane and 98.5% O2), animals
were placed on a heating pad in a supine position (n  6 per group).
Echocardiographic images were acquired using a Sonos 5500 ultra-
sound system with a 15 MHz linear probe (Philips, Bothell, Washing-
ton) as described previously.15 Two-dimensional LV short-axis views
were acquired at the papillary muscle level and M-mode recordings
were made. Depth settings were adjusted to maximize frame rate
(220–260 Hz) and optimize temporal resolution. The interventricular
septal thickness in diastole and the left ventricular end-diastolic and
end-systolic dimensions were measured using three consecutive
cycles. Fractional shortening and heart rate were calculated. Echocar-
diography was performed at day 7 and 14.
Tissue collection and histology
At the end of the 14 days treatment, animals were sacrificed and body
weight, atrial, right ventricular and left ventricular weights were
measured. Upon tissue harvest, one third of the left ventricle (base)
was separated for histological analysis approximately at the level of
the papillary muscles and the remaining tissue was frozen in liquid
nitrogen. Interstitial fibrosis was determined on formalin fixed,
paraffin-embedded 4 mm thick whole left ventricular sections using
picrosirius red staining (n = 6–10 per group). The density of collagen
(pixel number) in heart sections was measured under polarized light
based on its birefringement property at 200 magnification in areas
selected randomly, and was expressed as a percentage in relation to
the total pixel number.
Real-time polymerase chain reaction
Approximately 70–80 mg of frozen left ventricular tissue was used for
total RNA extraction using Stat-60 (Tel-Test Co, Friendswood, USA).
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Single strand cDNA was synthesized by Im-Prom II reverse transcrip-
tase according to the manufacturer’s instructions (Promega, South-
ampton, UK) from 1000 ng RNA. Cardiac hypertrophy markers such
as atrial natriuretic peptide (ANP), skeletal muscle actin (SKMactin)
and cardiac fibrosis markers such as procollagen I and III, thrombos-
pondin 1, and osteopontin were measured (n = 5–6 per group). All
genes were normalized to 18S level in individual samples that were
measured in duplicates. In addition, PPARg1, adiponectin, and
reduced nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase subunits (Nox2, Nox4, p22phox, p67phox) mRNA level
were also quantified. Real-time polymerase chain reaction (PCR) was
performed with SYBR Green technology using Prism 7900 HT
system (Applied Biosystems, Warrington, UK). Primer sequences are
listed in Table 1.
Allele-specific reverse transcriptase–
polymerase chain reaction
Forward primers: WT: 50-gacagacatgagccttcaccc-30 detects the WT
allele, whereas P465L: 50-cagacatgagccttcacct-30 detects the mutated
allele. Common reverse primer: 50-gggtgggactttcctgctaa-30. Polymerase
chain reaction was performed using the Power SYBR Green PCR
Mastermix (Applied Biosystems) with and 100 nM primers. Cycling:
2 min at 508C, 10 min at 958C, then 40 cycles of 15 s at 958C and
1 min at 668C. These conditions were set up in order to minimize
the cross amplification of alleles. To discard contaminants and RNA,
control was used we use as template for the quantitative real-time
PCR under the same conditions used in the validation experiments.
For mathematical analysis, the crossing points (Ct) values were used
for each transcript. The Ct is defined as the point at which fluorescence
of the transcript rises significantly above the background fluorescence.
The ‘fit point method’ was performed in the ABI7900HT platform,
at which Ct was measured at a constant fluorescence level. Differences
in expression between groups were assessed by Pair Wise Fixed
Reallocation Randomization Test using the Relative Expression
Software Tool.16 Data were corrected using the geometrical average
of four different housekeeping genes. Level of probability was set at
P, 0.05.
Serum biochemical parameters
Serum glucose (G), free fatty acid (FFA), cholesterol, triglyceride (TG),
insulin, leptin, and adiponectin levels were determined14 by commer-
cially available tests from fed animals at the end of the 14 days treat-
ment with AngII or saline in WT and P465L heterozygous mice.
There were no significant changes in G, TG, FFA, cholesterol, insulin,
and leptin levels among groups. Liver was not steatotic in any of the
groups at the end of treatment. Dual-energy x-ray absorptiometry17
(Lunar Corp., GE Healthcare, MD, USA) analysis confirmed that
total fat percentage and body weight did not change significantly
among groups.
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Table 1 Primer sequences used for reverse transcriptase-polymerase chain reaction
Protein Gene Allocation Sequences 50!30
Procollagen I Col 1a1 NM_007742 F: CCTCAGGGTATTGCTGGACAAC
R: TTGATCCAGAAGGACCTTGTTTG
Procollagen III Col 3a1 NM_009930 F: AGGAGCCAGTGGCCATAATG
R: TGACCATCTGATCCAGGGTTTC
Osteopontin Spp1 NM_009263 F: GATTTGCTTTTGCCTGTTTGG
R: TGAGCTGCCAGAATCAGTCACT
Thrombospondin1 Thbs1 NM_011580 F: GGGGCAGGAAGACTATGACA
R: CTCCCCGTTTTTGTCTGTGT
PPARg1 Pparg NM_011146 F: TTTAAAAACAAGACTACCCTTTACTGAAATT
R: AGAGGTCCACAGAGCTGATTC
Probe: GAGAGATGCCATTCTGGCCCAC
Adiponectin AdipoQ NM_009605 F: CAGTGGATCTGACGACACCAA
R: TGGGCAGGATTAAGAGGAACA
Probe: AGGGCTCAGGATGCTACTGTTGCAAGC
Atrial natriuretic peptide precursor Nppa NM_008725 F: TGCGGTGTCCAACACAGATC
R: CCTTCATCTTCTACCGGCATCTT
Skeletal muscle Acta1 NM_009606 F: CACCCAGGGCCAGAGTCA
Alpha-actin R: AGAGCGGTGGTCTCGTCTTC
Nox2 Cybb NM_007807 F: TGTGTCGAAATCTGCCTCTCCTTT
R: TTCCTGTCCAGTTGTCTTCGAA
Nox4 Nox4 NM_015760 F: CCGGACAGTCCTGGCTTATC
R: TGCTTTTTATCCAACAATCTTCTTGTT
p22phox Cyba NM_007806 F: TGGACGTTTCACACACAGTGGT
R: TGGACCCCTTTTTCCTCTTT
p67phox Ncf2 NM_010877 F: CTTCATGTTGGTTGCCAATG
R: AAGCTGTTTGCCTGTGAGGT
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Statistical analysis
Data are expressed as mean+ SEM. One-way ANOVA was used
to compare data among groups with Bonferroni post hoc test using
Graphpad Prism software. Level of significance is indicated in
Figures 1–5 and Table 2.
Results
Angiotensin II administration increases
systolic blood pressure and cardiac
hypertrophy to a similar extent in
wild-type and P465L peroxisomal
proliferators activated receptor gamma
mice
We investigated the effect of chronic AngII administration on systo-
lic blood pressure and development of cardiac hypertrophy in WT
and PPARg defective mice. Baseline systolic blood pressure was not
significantly different between the WT and P465L heterozygous
mice (100.9+5.8 vs. 103.2+7.3 mmHg, respectively). Two
weeks administration of AngII increased systolic blood pressure to
a similar extent in WT and PPARg defective mice. Changes in
blood pressure after 7 and 14 days of AngII treatment are shown
in Figure 1. No differences were observed in basal heart weight to
body weight ratio between WT/SAL mice (4.63+0.08) and
P465L/SAL mice (4.72+0.06). As expected, AngII treatment signifi-
cantly increased Hw/Bw ratio, but to a similar extent in both geno-
types (5.44+0.15 vs. 5.62+0.18, respectively, Figure 1B).
Increased cardiac fibrosis in angiotensin II
treated P465L mice compared with
wild-type mice
Despite having similar increases in blood pressure and heart
hypertrophy, the PPARg P465L mice developed increased fibrosis
in response to AngII compared with WT littermates. Repre-
sentative images (total of 40 magnification) acquired from
paraffin-embedded sections are illustrated in Figure 2A. Picrosirius
red staining shows that interstitial collagen staining was minimal
in saline-treated WT (i) and P465L (iii) mice, whereas chronic
administration of AngII induced a cardiac fibrotic response that
was more severe in P465L (iv) mice. Quantification under polar-
ized light (total of 200 magnifications) confirmed a similar
Figure 1 (A) The effects of AngII on systolic blood pressure
(SBP, mmHg) measured by tail cuff plethysmography in wild-type
(WT) and heterozygous P465L mice. AngII increased SBP simi-
larly in WT and P465L PPARg mice compared with saline-treated
controls. *P, 0.05 vs. day 0. (B) The effects of subcutaneous
AngII infusion on heart weight to body weight ratio (Hw/Bw) at
the end of 14 days saline (SAL) or angiotensin II (AngII) treatment
in WT and P465L heterozygous mice. AngII significantly increased
Hw to Bw ratio to a similar degree in WT and P465L PPARg
groups. *P, 0.05 vs. saline-treated controls.
Figure 2 (A) Representative images of collagen deposition
stained by picrosirius red in saline and AngII-treated WT and
P465L mice at total of 40 magnification. (i) WT/SAL, (ii) WT/
AngII, (iii) P465L/SAL, and (iv) P465L/AngII. (B) Quantification
of fibrosis in saline and angiotensin II treated WT and P465L
mice under polarized light at total of 200 magnification
(n = 6–10 per group). Six randomly selected areas were quanti-
fied and averaged per left ventricular section. *P, 0.05 vs.
WT/SAL or WT/AngII groups.
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degree of basal fibrosis in saline-treated WT and P465L mice
(0.48+0.1 vs. 0.53+0.04%, respectively, Figure 2B). More impor-
tantly, AngII treatment increased fibrosis in WT mice (0.75+
0.17%, Figure 2B) by 55% compared with saline-treated WT
mice, whereas heterozygous P465L treated with AngII showed a
more severe 140% increase in interstitial fibrosis (1.27+ 0.3%,
P, 0.05 vs. WT, Figure 2B).
Normal functional echocardiographic
parameters in angiotensin II treated
wild-type and P465L mice
Under the experimental conditions investigated, no differences in
heart rate (Table 2) or functional parameters were found in
P465L heterozygous mice and in WT littermates after 14 days
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Table 2 Echocardiographic parameters at day 7 and at day 14 during saline or angiotensin II treatment in wild-type and
heterozygous P465L mice
WT/SAL P465L/SAL WT/AngII P465L/AngII
Day 7
IVSD (mm) 0.83+0.05 0.77+0.03 1.02+0.07* 0.98+0.06*
LVESD (mm) 3.01+0.07 3.22+0.10 2.98+0.07 3.04+0.18
LVEDD (mm) 4.37+0.04 4.48+0.13 4.22+0.10 4.31+0.10
FS 31.0+2.2 28.0+3.2 29.3+1.3 29.6+3.0
HR (beats min21) 413+11 451+52 480+16 486+20
Day 14
IVSD (mm) 0.79+0.01 0.82+0.02 1.02+0.07* 1.04+0.06*
LVESD (mm) 3.37+0.14 3.17+0.4 3.00+0.17 3.03+0.19
LVEDD (mm) 4.59+0.9 4.56+0.12 4.25+0.9 4.32+0.12
FS 26.7+1.7 30.3+2.6 29.6+2.9 30.2+2.8
HR (beats min21) 447+16 477+54 491+29 509+22
IVSD, interventricular septal thickness; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension; FS, fractional shortening; HR, heart rate.
*P, 0.05 vs. WT/Sal or P465L/Sal, respectively.
Figure 3 Reverse transcriptase–polymerase chain reaction (RT–PCR) analysis of hypertrophy, fibrosis marker genes, and NADPH oxidase
subunit genes in saline and angiotensin II treated WT and P465L mice. Expression of hypertrophy and fibrosis marker genes increased during
AngII treatment; this increased expression level was higher in heterozygous P465L mice. PPARg1 and adiponectin (AdipoQ, PPARg target gene)
were not changed significantly among groups. *P, 0.05 vs. WT/SAL; †P, 0.05 vs. P465L/SAL; $P, 0.05 vs. WT/AngII.
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AngII treatment. As expected, AngII treatment increased inter-
ventricular septal thickness by day 7 in both the WT/AngII and
P465L/AngII groups to a similar extent and by day 14 no
further increase in hypertrophy was detected (Table 2). Of
note, both the left ventricular end-systolic and end-diastolic par-
ameters, as well as fractional shortening were similar in WT and
P465L heterozygous mice after 14 days of AngII treatment
(Table 2).
The effect of chronic angiotensin II
treatment on hypertrophy and fibrosis
marker genes and NADPH oxidase
subunit genes
We investigated whether ANP and SKMactin, molecular markers
of cardiac hypertrophy, were upregulated in our experimental
model. No significant differences in basal gene expression
between WT/SAL and P465L/SAL groups were observed
(Figure 3A), whereas AngII-treated PPARg P465L mice showed
increased expression of ANP and SKMactin compared with their
WT littermates (Figure 3A).
Similarly, expression of procollagen I and III, osteopontin, and
thrombospondin1, genes encoding extracellular matrix proteins
typically synthesized de novo during the early phase of fibrosis,
was markedly upregulated in AngII-treated heterozygous P465L
mice in comparison with AngII-treated WT littermates
(Figure 3B). The increased expression of these fibrosis markers
agreed with the increased fibrotic response observed histologically.
Interestingly, basal expression level of these profibrotic genes did
not significantly differ between saline-treated WT and heterozy-
gous P465L mice (Figure 3B).
Recent studies indicate that the increased interstitial cardiac
fibrosis induced by chronic AngII infusion involves the activation
of NADPH oxidases, reactive oxygen species-generating enzymes
involved in redox signalling and enhanced gene expression.8,15
We therefore investigated whether alterations in NADPH oxi-
dases may be involved in the enhanced profibrotic effects of
AngII in mice with defective PPARg function. Measurement of
the relative expression of Nox2, Nox4, p22phox, and p67phox
subunits of NADPH oxidase in all groups showed that only
Nox4 was significantly increased in the AngII-treated P465L mice
compared with AngII-treated WT mice, although the other sub-
units all showed a tendency to increase their mRNA level during
AngII treatment (Figure 3C).
Angiotensin II reduces adiponectin level
in the serum in wild-type but not in P465L
heterozygous mice
Our group has shown previously that P465L dominant-negative
mutation in PPARg reduces adiponectin expression in adipose
tissue.14 However, this decrease in adiponectin level did not
result in insulin resistance in this mouse model.14 We have found
that, unlike in P465L heterozygous mice, AngII treatment in WT
animals significantly reduced serum adiponectin level compared
with saline-treated controls. Interestingly, this level remained sig-
nificantly higher than that was found in AngII-treated P465L het-
erozygous mice (Figure 4).
Detection of wild-type and mutant alleles
in heart RNA samples
We attempted to detect mutant PPARg allele in heterozygous
mouse heart samples to confirm the presence of mutated allele.
Figure 5 Expression level of total PPARg in wild-type and heterozygous mutant mice and percentage of WT and mutant PPARg alleles in the
heterozygous mutant mice. Level of probability was set at P, 0.0516 (n = 10 per group).
Figure 4 Serum level of adiponectin in saline and AngII-treated
WT and P465L heterozygous mice at the end of 14 days treat-
ment. Level of significance is indicated as $P, 0.001 vs. WT/
Sal; *P, 0.01 vs. WT/Sal; †P, 0.01 vs. WT/AngII.
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This is illustrated in Figure 5. mRNA expression levels of total
PPARg was reduced by 50% in the P465L heterozygous mice
compared with WT mice. In addition to this, the WT and
mutant alleles were expressed at similar levels each, one repre-
senting 50% of the total PPARg.
Discussion
In this study, we show that hypertension induced by chronic AngII
administration synergises with defective PPARg function in vivo to
induce cardiac fibrosis. Using a ‘humanized’ knock-in mouse
model recapitulating a human dominant-negative point mutation
in the nuclear receptor PPARg, no significant alterations were
detected in basal cardiac parameters (e.g. Hw/Bw ratio) or fibrosis
level. However, in the presence of AngII-induced hypertension,
defective PPARg activity resulted in an increased cardiac fibrosis
compared with their WT littermates. This differential fibrotic
response was not the result of differences in blood pressure or
the degree of cardiac hypertrophy, as both WT and heterozygous
P465L mice had similar increases in systolic blood pressure up to
150 mmHg and their Hw to Bw ratios after AngII treatment were
also similar.
Structural remodelling during sustained hypertension is a well-
recognized response of the heart which typically results in both
cardiomyocyte hypertrophy and interstitial fibrosis. It is driven by
numerous mechanisms including mechanical stress and local and
systemic neurohumoral pathways such as activation of the
renin–angiotensin system. Although hypertrophy and interstitial
fibrosis often co-exist, they may to a significant extent be indepen-
dently regulated. The development of fibrosis involves significant
rearrangement of components of the extracellular matrix,
increased oxidative stress driven by NADPH oxidase,8 prolifer-
ation of fibroblasts, biosynthesis of different collagen isoforms,18
and the upregulation of other membrane-linked glycoproteins
such as osteopontin19 and thrombospondin.20 It is known that
severe interstitial fibrosis in response to long-term stress may be
associated with diastolic dysfunction, arrhythmia, and eventually
pump failure.
There is data that suggest a beneficial role of PPARg in the
cardiac remodelling process as indicated by pharmacological evi-
dence that specific PPARg ligands may prevent or reduce synthesis
and deposition of collagen and other matrix proteins during the
fibrotic response. For example, pioglitazone reduced myocardial
fibrosis and collagen content during heart failure development,
resulting in improved contractile function of mouse hearts.11 Rosi-
glitazone, another PPARg agonist, prevents cardiac fibrosis in
mineralocorticoid induced hypertension in rats21 and also, in rats
subjected to aortic constriction.13 Finally, ciglitazone inhibited peri-
vascular and interstitial fibrosis in mice that underwent aortic
banding, with concomitant improvement of heart function.3
Using a genetic approach, we have shown in the present study
that in the presence of AngII-induced hypertension, expression
of the P465L PPARg human mutation is associated with increased
expression of profibrotic genes such as procollagen I, III, and
osteopontin. Previous data have suggested the involvement of
osteopontin in myocardial fibrosis and in fact, mice lacking osteo-
pontin are unable to develop fibrosis resulting in accelerated
myocardium dilation.22 Our data indicate that osteopontin is
barely expressed in the heart of WT and our PPARg P465L
mice, after AngII-induced hypertension osteopontin is increased
up to 17-fold in WT and up to 35-fold in the P465L mice. Other
examples of profibrotic genes are thrombospondin 1 and 2, both
important regulators of extracellular matrix remodelling by activat-
ing TGF-b. More specifically, there is evidence that thrombospon-
din 2 seems to contribute to the progression of human heart
failure.20 In our study, we found that heterozygous P465L mice
had increased thrombospondin 1 level compared with WT mice
after AngII treatment and in agreement with increased histological
evidence of cardiac fibrosis we also found an increased expression
collagen isoforms. Previous studies have suggested that stimulation
with extrinsic PPARg agonists exerts an anti-fibrotic effect,
whereas the current study indicates that endogenous PPARg
may exert anti-fibrotic effects in the context of hypertension,
which are absent in the heterozygous P465L mice. In keeping
with this idea, a direct transcriptional repressing effect of PPARg
has been already shown for osteopontin expression through its
binding to a PPAR response element sequence in the osteopontin
promoter.23 There is also evidence that PPARg dysfunction may
directly potentiate collagen synthesis through the interaction of
the CIITA/RFX5 transcription factor complex on the collagen
gene promoter.24 Taken together, these data suggest that in our
mouse model the presence of the dominant-negative PPARg
mutation may have impaired the repressor function of PPARg in
preventing cardiac fibrosis during AngII challenge, thereby allowing
enhanced transcription of these particular profibrotic genes.
In contrast to the data regarding interstitial fibrosis, angiotensin
II did not increase Hw to Bw ratio or Hw to tibia length (data not
shown) in heterozygous P465L mice relative to WT mice. This
suggests that the pro-fibrotic effects associated with this specific
mutant of PPARg in the presence of increased AngII levels are dis-
tinct from mechanisms driving cardiac hypertrophy at least under
these experimental conditions, in contrast to previous studies.10
We also found that there was no overt contractile dysfunction in
the heterozygous P465L mice compared with WT mice as
assessed by echocardiography, although the presence of more
subtle differences remains possible and would require in vivo ana-
lyses and/or more prolonged treatment to exclude.
Previous data suggest that decreased adiponectin expression
may be implicated in heart failure progression in humans.25 Fur-
thermore, in a similar experimental model to ours, adiponectin
KO mice during AngII-induced hypertension showed substantially
increased interstitial fibrosis as well as cardiac hypertrophy than
their WT littermates.26 In a permanent ligation induced chronic
heart failure model, the lack of adiponectin significantly increased
the level of compensatory hypertrophy, interstitial fibrosis, and
left ventricular dysfunction.27 On the contrary, in the same
study, adiponectin via adenoviral delivery in WT animals protected
the heart against these consequences of chronic ligation of LAD
suggesting anti-fibrotic role of adiponectin.27 In our mouse
model, P465L dominant-negative mutation in PPARg reduced adi-
ponectin expression in the heart and adipose tissue (indicated by
lower serum level) which may be contributory to the increased
level of cardiac fibrosis under hypertensive conditions. We
suggest that reduced adiponectin level in the absence of insulin
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resistance during this initial phase of hypertension may contribute
to increased cardiac fibrosis before left ventricular dysfunction
occurs. However, this hypothesis needs confirmation by further
studies.
Our mouse model is not insulin resistant in contrast to humans,
a difference that likely arises due to discrepancy in the distribution
and function of their various fat pads.28 Nevertheless, both direct
and indirect roles of adipose tissue in blood pressure regulation
(e.g. perivascular fat) and heart function (e.g. epicardial fat) have
been established in humans as well as in animal models. For
example, adipokines such as leptin29 and visfatin30 in mice have
been shown to directly regulate cardiac function under experimen-
tal conditions. In addition, insulin resistance depends on the array
of adipokines secreted by various visceral and subcutaneous fat
pads underlying one particular pathomechanism of the metabolic
syndrome in humans.1,31,32 The observed increased fibrotic
cardiac (and not metabolic) phenotype in our study in heterozy-
gous P465L mice under hypertension may be the result of
altered expression of PPARg target genes such as adiponectin
in the heart and fat (Figures 3 and 4) but not of leptin. Similar
to those humans with dominant-negative mutation in
PPARg,1 P465L heterozygous mice also have lower expression
of adiponectin in adipose tissue as well as in the heart. Another
adipose secreted adipokine, leptin which is not regulated by
PPARg shows no correlation with any of the phenotypes in
the presence of the mutation in humans1 and in our study (data
not shown).
From the point of view of relevance to human disease, our data
suggest that patients harbouring this mutation or similar ones31,32
may be at increased risk of developing cardiac fibrosis particularly
in the context of hypertension. The use of our P465L PPARg
mouse model to study the role of PPARg in the heart has the
advantage that this mouse model has a much less severe metabolic
phenotype than in humans,28 at least when animals are not in posi-
tive energy balance.14 Thus, elucidation of the synergistic effect
between defective PPARg function and cardiac-specific fibrotic
response in this murine model is facilitated in the absence of
other complex metabolic phenotypes.
Although these PPARg mutations are rare in humans,31,32 these
patients exist and in fact it may be possible that their prevalence
may increase as increased knowledge allows targeting of specific
subsets of patients such as, for example, patients with cardiac
phenotypes. Our observations should emphasise that control of
blood pressure in these patients may be of paramount import-
ance to prevent cardiac-specific complications. Another less
obvious implication is the relevance that these observations may
have in the management of more common forms of metabolic
syndrome. There is evidence from animal models and studies in
humans that in parallel with the development of obesity, insulin
resistance, and metabolic alterations, levels of PPARg tend to
decrease initiating a vicious cycle leading to metabolic failure.33
This suggests that decreased PPARg levels in these patients may
synergise with highly prevalent hypertension to accelerate
cardiac fibrosis. Thus, these considerations should fuel future
translational research in humans to elucidate the relevance of
the synergy between PPARg agonism and hypertension in
humans.
In summary, here we provide evidence using a humanized mouse
model recapitulating a well-characterized human mutation that
defective PPARg function synergises with high blood pressure to
induce cardiac fibrosis in vivo. This observation indicates that
control of blood pressure should be prioritized in patients affected
by these PPARg mutations to prevent cardiac complications. We
speculate that the knowledge obtained from these experiments
also supports the need for strict blood pressure control in other
forms of obesity and insulin resistant states where levels of
PPARg may be decreased in the context of the metabolic
syndrome.
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